Clinical trials
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) clinical trials
Below are recruiting allogeneic hematopoietic stem cell transplantation (hsct) clinical trials, each written for real people, not researchers. We’re tracking 117 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07028112Recruiting
Iron and liver health after stem cell transplant
This study looks at how too much iron in the body (from past transfusions) affects the liver in people who had a stem cell transplant at least 10 years ago. It will help doctors understand who needs special monitoring for liver problems.
ParisAges 18 years+ - NCT07059026Recruiting
Thrombotic microangiopathy after stem cell transplant in adults
This study looks at people who have a blood clotting problem called TMA after a stem cell transplant from a donor. It gathers information from routine checkups to learn more about this condition.
Buenos AiresAges 18 years+ - NCT07105579RecruitingPhase 2
Blinatumomab and donor cells after transplant for high-risk B-ALL
This trial tests whether giving two drugs—blinatumomab (an immunotherapy) and donor lymphocyte infusions (white blood cells from your donor)—can help prevent leukemia from coming back after a stem cell transplant for high-risk B-ALL. It is for people who are in remission with no sign of leukemia cells.
HangzhouAges 14–65 - NCT05531786RecruitingPhase 1/Phase 2
Pacritinib for hard-to-treat chronic graft-versus-host disease
This early-phase study tests pacritinib, a targeted medicine, for chronic graft-versus-host disease (cGVHD) that hasn’t improved after prior treatments. If you qualify, the goal is to reduce cGVHD symptoms and improve how well you function after a stem cell transplant.
Miami, FloridaAges 18–120 - NCT07253129Recruiting
Stem cell transplant study for T-cell lymphoma patients with partial response
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07297173RecruitingPhase 1
Immune cell infusion plus transplant for tough leukemia
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
BeijingAges 15 years+ - NCT07362095RecruitingPhase 1/Phase 2
Luspatercept for anemia after a stem cell transplant
This study tests a drug called luspatercept to see if it can help people who have low red blood cells (anemia) after a stem cell transplant for leukemia. It may improve your energy and reduce the need for blood transfusions.
Guangzhou, GuangdongAges 18–70 - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT02007356RecruitingPhase 2
Donor immune cell infusions for viral infections after stem cell transplant
This trial studies whether directly infusing donor-made immune cells (virus-fighting T-cells) is safe and feasible in people who still have viral infections after a stem cell transplant. It may help your body control infections from adenovirus, CMV, or EBV when standard antiviral treatments aren’t working.
BaselAges 18–65 - NCT01174108RecruitingPhase 2
Stem cell transplant with donor T-cells for severe bone marrow failure
This Phase 2 study tests a specific type of donor stem cell transplant for severe bone marrow failure conditions, aiming to improve cure rates while reducing transplant risks. It includes people with diseases like severe aplastic anemia and certain bone marrow disorders, especially when standard transplant plans feel too risky.
Baltimore, MarylandAges 4–80 - NCT01420562Recruiting
Posaconazole medicine study in transplant patients with mouth sores
This study looks at how posaconazole (an antifungal medicine) moves through the body in people who recently had an allogeneic stem cell transplant and have mouth sores (mucositis). It may help clinicians choose the safest and most effective dosing for preventing serious fungal infections.
Leuven, Vlaams-BrabantAges 18–75 - NCT01861106RecruitingPhase 2
Bone marrow transplant for people with GATA2 gene changes
This trial tests whether an allogeneic bone marrow (stem cell) transplant can improve outcomes for people with GATA2 gene changes or “MonoMAC” syndrome. It aims to rebuild a healthier immune system in patients who have serious infections and immune cell deficiencies.
Bethesda, MarylandAges 6–70 - NCT06905509RecruitingPhase 2
Epcoritamab with chemo and stem cell transplant for large B-cell lymphoma
This trial tests adding epcoritamab (an immune therapy that helps your body fight cancer) to standard chemotherapy followed by a stem cell transplant. It is for people with large B-cell lymphoma that has come back or not responded to initial treatment.
Sacramento, CaliforniaAges 18 years+ - NCT07400328RecruitingPhase 2
Stem cell injection to prevent severe mouth sores in transplant
This trial is testing a single injection called Amimestrocel to prevent severe mouth sores in people getting a stem cell transplant. The study is for adults who are receiving high-dose conditioning with total body irradiation or melphalan, which often cause painful mouth inflammation.
Suzhu, JiangsuAges 18–65 - NCT07425782RecruitingPhase 2
Venetoclax and azacitidine as consolidation for high-risk AML
This trial tests the combination of venetoclax (a targeted pill) and azacitidine (a chemotherapy-like drug) as consolidation therapy after initial treatment in adults with high-risk acute myeloid leukemia (AML) who have achieved remission and are planning a stem cell transplant. The goal is to see if this combination helps prevent relapse before transplant.
Suzhou, JiangsuAges 18 years+ - NCT07463651RecruitingPhase 3
Gilteritini vs Sorafenib after transplant for FLT3-ITD AML
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
Suzhou, JiangsuAges 14–70 - NCT07499284Recruiting
Haplo-Cord Stem Cell Transplant for Aplastic Anemia
This trial tests a new way of using a mix of donor stem cells (from a half-matched family member and a cord blood unit) to treat aplastic anemia, a condition where the bone marrow stops making enough blood cells. The goal is to see if this transplant approach is safe and helps rebuild healthy blood cells.
Suzhou, JiangsuAges 14 years+ - NCT07500753Recruiting
Study of a conditioning regimen for older adults with hard-to-treat leukemia or MDS
This trial tests a chemotherapy combination (Clad-LABU) to prepare older patients for a stem cell transplant. It is for people aged 50 or older with relapsed or refractory AML or high-risk MDS.
Suzhou, JiangsuAges 50 years+ - NCT07569055Recruiting
Fungal Infections After Stem Cell Transplants: Long-Term Study
This study follows patients who have received a stem cell transplant from a donor to track and understand fungal infections that can occur afterward. By studying this carefully, researchers hope to better prevent and treat these serious infections in future patients.
Beijing, Beijing MunicipalityAges Any age - NCT07569653RecruitingPhase 4
CMV Prevention After Stem Cell Transplant Using Blood Tests
This trial tests whether doctors can safely stop a CMV prevention medication (letermovir) earlier by using blood tests to check your immune system's strength. CMV is a virus that can become dangerous after stem cell transplant, and this study aims to prevent it while minimizing unnecessary medicine.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07572669RecruitingPhase 2
Moxibustion for Steroid-Resistant Graft-Versus-Host Disease
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
Wuhan, HubeiAges 14–65 - NCT07583888RecruitingPhase 2/Phase 3
VABu Conditioning for Older Adults with Acute Myeloid Leukemia
This trial tests a chemotherapy regimen (VABu) combined with a stem-cell transplant for older adults (60+) with acute myeloid leukemia (a blood cancer) who previously responded well to Venetoclax-based treatment. The goal is to see if this approach improves outcomes after transplant.
Suzhou, JiangsuAges 60 years+ - NCT07162688Enrolling by invitationPhase 1/Phase 2
Omega-3 fatty acids to prevent graft-versus-host disease after stem cell transplant
This trial tests whether omega-3 fatty acids can help prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a donor. Omega-3 may reduce inflammation and lower the chance of this serious complication.
Fuzhou, FujianAges 18–65 - NCT07438067RecruitingPhase 1
EBV-targeted cell therapy after stem cell transplant
This trial tests a special immune cell therapy (EBV-AST) for people who have high levels of Epstein-Barr virus (EBV) in their blood after a stem cell transplant. The goal is to see if it can safely control the virus and prevent related complications.
BeijingAges 18–75
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for allogeneic hematopoietic stem cell transplantation (hsct)?
- Yes. Clin2 currently lists 117 recruiting allogeneic hematopoietic stem cell transplantation (hsct) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a allogeneic hematopoietic stem cell transplantation (hsct) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a allogeneic hematopoietic stem cell transplantation (hsct) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Hematopoietic Stem Cell Transplantation
- Allogeneic Stem Cell Transplantation
- Haploidentical Hematopoietic Stem Cell Transplantation
- Autologous Hematopoietic Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.